Global Cement Industry Reports 25% CO 2 Intensity Reduction and Calls for Urgent Government Action to Accelerate Net Zero Mission
17.11.2025 11:00:00 CET | Business Wire | Press Release
The extensive decarbonisation work being carried out by the global cement and concrete industry to cut CO₂ emissions is set out in a new global report launched at COP30 in Belem, Brazil. The report details latest industry data showing that the sector is making progress, and also emphasises the need for urgent global government input to help accelerate action.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117920702/en/
GCCA Cement and Concrete Industry Net Zero Action and Progress Report
The report finds that the industry has reduced the CO₂ intensity of cementitious products by 25% across the globe since 1990, and also sets out a series of policy recommendations that can pave the way for faster reductions.
Dominik von Achten GCCA President and Chairman of the Managing Board of Heidelberg Materials said: "Our industry is collaborating and innovating across every aspect of our manufacturing – finding new ways to work and deploying exciting technologies that are already making a genuine step change.
“However, to achieve the industrial scale transformation that our world needs, we cannot do it by ourselves – our industry needs the support of governments, policymakers, stakeholders, and our allies across the built environment right now.”
The report calls for the urgent implementation of effective policies which promote the use of otherwise non-recyclable municipal and industrial waste as sustainable alternative fuels for cement kilns, as well as using construction demolition waste as recycled raw materials. Other key policies include a change in building codes to encourage the wider adoption of blended cement and concrete products, as well as the establishment of market-driven national carbon pricing mechanisms that incentivise decarbonisation and investment in clean innovation.
Thomas Guillot, Chief Executive of the GCCA said: “The breadth of activity we are seeing across our membership is truly inspiring, with great examples of projects and work across all decarbonisation levers, where enabling policies exist.
"Cement and concrete are essential materials for the world, but we know they are also essential to decarbonise. Despite our progress, we know that firm policy action across the world is fundamental to enabling us to accelerate our reductions.”
Four years on from the launch of its net zero roadmap, the GCCA’s Cement and Concrete Industry Net Zero Progress Report 2025/26 highlights the leading role that the companies across the world are playing in decarbonisation.
The report highlights more than 60 standout decarbonisation projects from GCCA member companies and partner associations, including:
CO₂ reductions through using waste materials (“alternative fuels”) to replace fossil fuels, use of decarbonated raw materials, energy efficiency measures and innovations such as use of hydrogen and kiln electrification.
- Examples include Fletcher’s Golden Bay plant and JSW’s Nandyal and Shiva plants. Votorantim Cimentos has pioneered in Turkey the use of biomass waste. At its Yozgat plant the alternative fuel in the main burner is primarily corn stalks. At its Hasanoğlan plant, biomass is used in the calciner line.
- Limak Cement has used construction demolition waste in commercial production, Molins has commercialised calcined clay cement into the Spanish market and TCC Holdings’ subsidiary CIMPOR is driving African calcined clay production. CRH’s cement plant in Rohožník, Slovakia has made clinker efficiencies through the replacement of 20% raw materials with alternatives.
Acceleration of Capture Utilisation and Storage (CCUS) which accounts for 36% of the industry’s planned CO2 reductions, according to the GCCA Roadmap.
- Examples include the launch of world’s first industrial sized carbon capture cement plant at Brevik, Norway, run by Heidelberg Materials in June 2025. Other examples include Breedon, Cementir Holding, CNBM, GCC, Holcim, JCA, JSW, TITAN and UltraTech. Publicly announced projects are collated and made available to see on the GCCA/LeadIT green cement technology tracker.
Increasing use of alternative energy sources.
- Examples include solar power advancement at Cemex plants in Croatia, and UltraTech’s renewable energy project in Gujarat.
Lower carbon Concrete and circularity, and design and construction.
- Holcim and Seqens have built the Recygénie 220-unit social housing complex in Paris using a custom concrete, the world’s first building using 100% recycled concrete. Taiheiyo Cement’s CARBOCATCH system is producing lower carbon concrete by using waste materials that have absorbed CO₂.
The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Government of Canadasaid: “Concrete is at the heart of the world’s growing economic ambitions and infrastructure needs, from housing to roads to energy and trade hubs. As demand is accelerating, industrial decarbonization has never been more important.
“Canada is proud of the work and achievements of the Cement and Concrete Breakthrough, and COP30 marks an opportunity to deliver on progress made towards our first set of Priority Actions.”
Read the full report: https://gccassociation.org/cement-and-concrete-industry-net-zero-action-and-progress-report/
About industry emissions data
Every year the GCCA publishes our latest industry GNR (“GCCA in NumbeRs”) data. The GNR is a global database that collects (through a credited third party, PwC) and transparently publishes a set of key industry sustainability data. The data is collected according to the Cement CO₂ and Energy Protocol, and available data goes back to 1990 as a reference point, so we are able to assess the progress that is underway.
The GNR is a key tool in how key sustainability progress is monitored and reported.
Latest data
In 2025, we collected data for 2023, to meet stipulated lag period required by Competition and Markets Authority (CMA) of 2 years.
- The 2023 Cement Industry GNR data* show a 25% reduction in CO2 per tonne of cementitious has been achieved since 1990
- The proportion of alternative fuels used is 12 times greater than in 1990
- Energy efficiency has improved by 18%
- Clinker to Cementitious ratio shows an improvement of 10.68% since 1990
* Note figures are rounded. Please refer to GCCA website for exact figures and comparisons and full GNR database. |
About the GCCA
The GCCA and its members account the majority of global cement production capacity outside of China, as well as a growing number of Chinese manufacturers. Member companies have committed to reducing and ultimately eliminating CO2 emissions in concrete, which currently account for around 7% globally, through implementation of the GCCA’s Concrete Future 2050 Net Zero Roadmap – the first heavy industry to set out such a detailed plan, Together, GCCA is committed to building a bright, resilient and sustainable concrete future for the industry and for the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251117920702/en/
Contacts
Notes to editors:
For photos of decarbonisation case studies please contact:
GCCACommunication@gccassociation.org.
For further information please contact: paul.adeleke@gccassociation.org.
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom